Navigation Links
DARA BioSciences, Inc. Announces Appointment of Dr. David J. Drutz to Board
Date:3/4/2008

RALEIGH, N.C., March 4 /PRNewswire-FirstCall/ -- DARA BioSciences(TM) (Nasdaq: DARA) announced today the appointment of David J. Drutz, MD to the Board of Directors. Dr. Drutz was appointed to fill a Board vacancy and will serve on the Company's Compensation Committee as well as Corporate Governance and Nominating Committee. The appointment was effective February 26, 2008.

Richard Franco, Sr., DARA's Board Chairman, commented, "It is a pleasure to announce David's appointment. Considering his varied background and successful experiences, David will add another positive dimension to our Board."

Dr. Drutz's background includes senior executive positions in the pharma and biotech industries. He is currently President of Pacific Biopharma Associates, LLC and a General Partner with Pacific Rim Ventures Company, Ltd. He serves as a director in both the public and private sectors, is a member of several scientific advisory boards, and holds a certificate of director education from the National Association of Corporate Directors.

About DARA BioSciences, Inc.

DARA BioSciences(TM), Inc. ("DARA") is a Raleigh, North Carolina-based development-stage pharmaceutical company that acquires promising therapeutic molecules and medical technologies directly or through investment in established companies. DARA focuses its therapeutic development efforts on small molecules from late preclinical development through phase 2 clinical trials. DARA is developing a portfolio of therapeutic candidates for neuropathic pain, metabolic diseases including type 2 diabetes, dyslipidemia and dermatological disorders. DARA has licensed promising drug development candidates from Kirin Pharmaceuticals of Japan, Bayer Pharmaceuticals Corporation, Massachusetts General Hospital and Nuada LLC.

For more information please contact the Company at 919-872-5578 or visit our web site at http://www.darabio.com.

All statements in this news release that are not historical are forward- looking statements within the meaning of the Securities Exchange Act of 1934 as amended. Such forward-looking statements are subject to factors that could cause actual results to differ materially for DARA from those projected. Those factors include risks and uncertainties relating to the company's ability to develop and bring new products to market as anticipated, the current regulatory environment in which the company develops and sells its products, the market acceptance of those products, dependence on partner, successful performance under collaborative and other commercial agreements, competition, the strength of DARA's intellectual property, the intellectual property of others and other risk factors identified in the documents DARA has filed, or will file, with the Securities and Exchange Commission. Copies of DARA's filings with the SEC may be obtained from the SEC Internet site at http://www.sec.gov. DARA expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward- looking statements contained herein to reflect any change in DARA's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based. DARA BioSciences and the DARA logo are trademarks of DARA BioSciences, Inc.


'/>"/>
SOURCE DARA BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Akers Biosciences, Inc. ABI or the Company Receipt of Further United States Military Contracts
2. Pressure BioSciences, Inc. to Discuss Third Quarter Financial Results and Provide Business Update
3. Pressure BioSciences, Inc. Reports Third Quarter 2007 Financial Results and Provides Business Update
4. DARA BioSciences, Inc. and Point Therapeutics, Inc. Announce Consummation of Merger
5. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
6. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
7. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
8. HEI, Inc. Announces Sale of RFID Division Assets
9. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
10. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
11. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... ... a Service (WaaS), today announced the integration of Clarity Intelligence Platform (CIP) into ... partners to offer real-time business intelligence (BI) to their small and medium business ...
(Date:2/12/2016)... ... ... Fisher House Foundation Chairman and CEO Kenneth Fisher joined Governor Brian Sandoval, ... Scott Bensing, and Peggy Kearns Director, VA Southern Nevada Healthcare System yesterday to dedicate ... be the first Fisher House in Nevada, and will provide free lodging for families ...
(Date:2/12/2016)... ... February 12, 2016 , ... The Jones Agency, a family ... eastern Texas, is launching a cooperative charity drive with the Tarrant Area Food Bank ... than 50,000 individuals and families in need, the Tarrant County Food Bank offers hope ...
(Date:2/12/2016)... Columbus, OH (PRWEB) , ... February 12, 2016 , ... ... families of the greater Columbus, OH area. The latest campaign focuses on the fight ... the disease. Donations are now being accepted here . , Carmen is a ...
(Date:2/12/2016)... ... February 12, 2016 , ... Donor Network West, the organ procurement ... announced a partnership with San Ramon Regional Medical Center. Under the collaboration, the first ... a way to accommodate a more certain time frame for donor families for the ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... February 12, 2016 ... vermerkt)   http://www.sedar.com ) und ... abrufbar.    --> http://www.sedar.com ... http://www.telestatherapeutics.com abrufbar.    --> ... heute seinen Konzernabschluss des zweiten Quartals ...
(Date:2/12/2016)... HOUSTON , Feb. 12, 2016  Memorial Hermann ... center Dwight Howard to bring a one-of-a-kind ... Hospital . Using cutting-edge technologies such as 360-degree video ... kids both virtually, then literally – giving the patients ... – and it was all caught on video ...
(Date:2/12/2016)... and Company (NYSE: LLY ) today announced that the ... patent would not presently be infringed by Actavis marketing pemetrexed ... Italy and Spain ... --> --> In ... Lilly,s patent would be indirectly infringed by Actavis marketing certain ...
Breaking Medicine Technology: